Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients

The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.

View original article
Contributor: Gina Kolata